Von willebrand factor in head and neck cancer

Sweeney, Joseph D.; Killion, Kathy M.; Pruet, Charles F.; Spaulding, Monica B.

doi:10.1002/1097-0142(19901201)66:11<2387::aid-cncr2820661123>3.0.co;2-u

Cited by 30 publications

(13 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…After adjustment in the multivariable models (Table ) our results remained statistically significant, identifying both ADAMTS‐13 and VWF as independent predictors of survival probability ( P < 0.05 and P < 0.001, respectively). This consolidated the literature data on an association of increased VWF and/or decreased ADAMTS‐13 with worse survival probability in colorectal cancer, cancer of the head and neck, lung cancer, and in Waldenström's macroglobulinemia …”

Section: Discussionsupporting

confidence: 75%

The role of ADAMTS‐13 and von Willebrand factor in cancer patients: Results from the Vienna Cancer and Thrombosis Study

Obermeier

Riedl

et al. 2019

Research and Practice in Thrombosis and Haemostasis

View full text Add to dashboard Cite

Cancer is associated with increased risk of developing venous thrombosis. Cancer patients were studied for ADAMTS‐13 and VWF levels and occurrence of venous thrombosis. Increased VWF in cancer patients is associated with a higher risk of venous thrombosis. Low levels of ADAMTS‐13 and/or increased VWF in cancer patients are associated with worse survival. Background Cancer‐associated venous thromboembolism (VTE) is an important complication in the course of a malignant disease. Low ADAMTS‐13 (a disintegrin‐like and metalloproteinase with thrombospondin type 1 motif 13) and increased von Willebrand Factor (VWF) levels in cancer patients have been described numerously. Objectives Investigation of the influence of ADAMTS‐13 and VWF on the probability of VTE and survival in malignancy. Patients/Methods In the framework of the ongoing prospective Cancer and Thrombosis Study (CATS) ADAMTS‐13 activity and VWF antigen levels were investigated in cancer patients. Results In total, 795 patients with various tumor types (364 female/431 male, median age 62 years) were included; of those, 56 developed VTE and 359 patients died during a median follow‐up time of 730 days. The hazard ratio (HR) of VTE per doubling of VWF level was 1.56 (95% confidence interval [CI] 1.13‐2.16) in multivariable competing risk analysis. ADAMTS‐13 levels showed no correlation with the incidence of VTE in univariate competing risk analysis. The HR of mortality per doubling of VWF level was 1.46 (95% CI 1.28‐1.66) and per SD increment of ADAMTS‐13was 0.90 (95% CI 0.81‐1.00) in multivariable Cox regression analysis. Patients with VWF >75th percentile and concomitant low (<25th percentile) or medium (25‐75th percentile) ADAMTS‐13 values had the highest probability of mortality (HR 4.31 and 4.75, respectively). Conclusions High VWF levels were significantly associated with the risk of developing VTE in cancer patients, whereas ADAMTS‐13 was not. Low ADAMTS‐13 and increased VWF levels were independently associated with worse overall survival.

show abstract

Section: Discussionsupporting

confidence: 75%

The role of ADAMTS‐13 and von Willebrand factor in cancer patients: Results from the Vienna Cancer and Thrombosis Study

Obermeier

Riedl

et al. 2019

Research and Practice in Thrombosis and Haemostasis

View full text Add to dashboard Cite

show abstract

“…However, MNGs that are high vascularized tumors have a benign course and much lower mortality rates 30. In a series of 28 patients with head and neck cancer, VWF levels were reported to be significantly higher in patients who died than in those who survived 31. In another series, VWF levels were significantly higher in 30 patients with malignant brain tumors as compared with 30 patients with benign brain tumors 32 but no regression analysis was performed to ascertain their prognostic value.…”

Section: Discussionmentioning

confidence: 99%

Prognostic value of preoperative von Willebrand factor plasma levels in patients with Glioblastoma

et al. 2016

View full text Add to dashboard Cite

Circulating biomarker for malignant gliomas could improve both differential diagnosis and clinical management of brain tumor patients. Among all gliomas, glioblastoma (GBM) is considered the most hypervascularized tumor with activation of multiple proangiogenic signaling pathways that enhance tumor growth. To investigate whether preoperative antigen plasma level of von Willebrand Factor (VWF:Ag) might be possible marker for GBM onset, progression, and prognosis, we retrospectively examined 57 patients with histological diagnosis for GBM and 23 meningiomas (MNGs), benign intracranial expansive lesions, enrolled as controls. Blood samples were collected from all the patients before tumor resection. Plasma von Willebrand Factor (VWF):Ag levels were determined by using a latex particle‐enhanced immunoturbidimetric assay. The median levels of vWF:Ag were significantly higher in GBMs than in meningiomas (MNGs) (183 vs. 133 IU/dL, P = 0.01). The cumulative 1‐year survival was significantly shorter in patients with VWF:Ag levels >200 IU/dL than in those with levels <200 IU/dL and increased VWF levels were associated with a threefold higher risk of death in GBM patients. Our data suggest that VWF:Ag could be a circulating biomarker of disease malignancy, that could be considered, in association with other genetic and epigenetic factors, currently available in the GBM management. Future studies should investigate whether plasma VWF:Ag levels could also be used to monitor therapeutic effects and whether it may have a prognostic value.

show abstract

“…In this context, it is interesting to note that numerous studies have shown that cancer patients have elevated levels of plasma VWF, in addition to other coagulation factors, which all may contribute to thrombotic risk. These include laryngeal (Paczuski et al ., 1999), renal (Oleksowicz et al ., 1999), colorectal (van duijnhoven et al ., 1993), cervical (Gadducci et al ., 1993), prostate (Ablin et al ., 1988), and head and neck cancers (Sweeney et al ., 1990). Moreover, Oleksowicz et al .…”

Section: Discussionmentioning

confidence: 99%

Role of von Willebrand factor in tumour cell‐induced platelet aggregation: differential regulation by NO and prostacyclin

Jurasz

Stewart²,

Radomski

et al. 2001

British J Pharmacology

View full text Add to dashboard Cite

1 We have studied the e ects of a novel agonist, solid-phase von Willebrand Factor (sVWF), on tumour cell-induced platelet aggregation (TCIPA). 2 Washed platelet suspensions were obtained from human blood and the e ects of HT-1080 human ®brosarcoma cells and sVWF on platelets were studied using aggregometry, phase-contrast microscopy, and¯ow cytometry. 3 Incubation of platelets with sVWF (1.2 mg ml 71 ) and HT-1080 cells (5610 3 ml 71 ) resulted in a two-phased reaction characterized ®rst by the adhesion of platelets to sVWF, then by aggregation. 4 TCIPA in the presence of sVWF was inhibited by S-nitroso-glutathione (GSNO, 100 mM) and prostacyclin (PGI 2 , 30 nM). 5 Platelet activation in the presence of tumour cells and sVWF resulted in the decreased surface expression of platelet glycoprotein (GP)Ib and up-regulation of GPIIb/IIIa receptors. 6 Pre-incubation of platelets with PGI 2 (30 nM) resulted in inhibition of sVWF-tumour cellstimulated platelet surface expression of GPIIb/IIIa as measured by¯ow cytometry using antibodies directed against both non-activated and activated receptor. In contrast, GSNO (100 mM) did not a ect sVWF-tumour cell-stimulated platelet surface expression of GPIIb/IIIa. 7 Flow cytometry performed with PAC-1 antibodies that bind only to the activated GPIIb/IIIa revealed that GSNO (100 mM) caused inhibition of activation of GPIIb/IIIa. 8 The inhibitors exerted no signi®cant e ects on TCIPA-mediated changes in GPIb. 9 Thus, sVWF potentiates the platelet-aggregatory activity of HT-1080 cells and these e ects appear to be mediated via up-regulation of platelet GPIIb/IIIa. 10 Prostacyclin and NO inhibit TCIPA-sVWF-mediated platelet aggregation. The mechanisms of inhibition of this aggregation by PGI 2 di er from those of NO.

show abstract

Von willebrand factor in head and neck cancer

Cited by 30 publications

References 11 publications

The role of ADAMTS‐13 and von Willebrand factor in cancer patients: Results from the Vienna Cancer and Thrombosis Study

The role of ADAMTS‐13 and von Willebrand factor in cancer patients: Results from the Vienna Cancer and Thrombosis Study

Prognostic value of preoperative von Willebrand factor plasma levels in patients with Glioblastoma

Role of von Willebrand factor in tumour cell‐induced platelet aggregation: differential regulation by NO and prostacyclin

Contact Info

Product

Resources

About